Search

Avacincaptad pegol

[L47696] AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a global estimate of 170 million individuals affected. … Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule.

Frangula purshiana bark

Amiloxate

Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35]. … Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].

Birch bark extract

[L42380] Two oleogel formulations of birch bark extract (Oleogel-S10, 10% of triterpene dry extract in sunflower oil) have been approved by the European Medicines Agency. … [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the

Enasidenib

orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.

Demegestone

Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.

Palmidrol

Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets). … A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection.

Quizartinib

[A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3. … maintenance monotherapy resulted in a 22% reduction in the risk of death.

Pralsetinib

[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. … Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.

Vutrisiran

[A249010] The Val30Met variant is the most prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and Japan. … [A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met).